Cases & Deals

Cellectis sells Swedish subsidiary Cellectis AB to Takara Bio

Clients Cellectis SA

Jones Day advised Cellectis, a leader in the development of adoptive immunotherapies based on engineered allogeneic CART cells (UCART), in the sale of its subsidiary Cellectis AB to Takara Bio Inc.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.